Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 7:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 67 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Bone Metastatic Castration-Resistant Prostate Cancer Clear all
Suspended Phase 1Phase 2 Interventional

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

NCT04071236
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Stage IVB Prostate Cancer AJCC v8
Interventions
Avelumab, Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Peposertib, Questionnaire Administration, Radium Ra 223 Dichloride
Drug · Procedure · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
32
States / cities
Duarte, California • Los Angeles, California • Orange, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 16, 2026, 7:56 PM EDT
Terminated Phase 2 Interventional Results available

Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer

NCT02215161
View directory record Official record
Conditions
Castration Levels of Testosterone, Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
Selinexor
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Sep 16, 2026, 7:56 PM EDT
Completed Phase 2 Interventional Results available

Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer

NCT03204812
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Durvalumab, Tremelimumab
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Sep 16, 2026, 7:56 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of KX2-391 for Treatment of Bone-Metastatic, Castration-Resistant Prostate Cancer

NCT01074138
View directory record Official record
Conditions
Bone-Metastatic, Castration-Resistant Prostate Cancer
Interventions
KX2-391
Drug
Lead sponsor
Athenex, Inc.
Industry
Eligibility
18 Years to 85 Years · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Chicago, Illinois • Baltimore, Maryland • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Sep 16, 2026, 7:56 PM EDT
Active, not recruiting Phase 2 Interventional

Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer

NCT03344211
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Cancer
Interventions
Enzalutamide, Laboratory Biomarker Analysis, Radium Ra 223 Dichloride
Drug · Other · Radiation
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
3
States / cities
Duarte, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 16, 2026, 7:56 PM EDT
Not listed Phase 2 Interventional Results available

sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

NCT04033432
View directory record Official record
Conditions
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents, Metastatic Prostate Adenocarcinoma, Progressive Disease, Prostate Carcinoma Metastatic in the Bone, Prostate Carcinoma Metastatic in the Soft Tissue, PSA Progression, Stage IVB Prostate Cancer AJCC v8, Testosterone Less Than 50 ng/dL
Interventions
Recombinant EphB4-HSA Fusion Protein
Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Los Angeles, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced Sep 16, 2026, 7:56 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

NCT03582475
View directory record Official record
Conditions
Bladder Small Cell Neuroendocrine Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Prostate Carcinoma Metastatic in the Bone, Prostate Neuroendocrine Neoplasm, Prostate Small Cell Carcinoma, Stage III Bladder Cancer American Joint Committee on Cancer ( AJCC) v8, Stage III Prostate Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8, Ureter Small Cell Carcinoma, Urothelial Carcinoma
Interventions
Carboplatin, Cisplatin, Docetaxel, Etoposide, Pembrolizumab
Drug · Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Sep 16, 2026, 7:56 PM EDT
Terminated Phase 2 Interventional Results available

Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency

NCT03442556
View directory record Official record
Conditions
ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Homologous Recombination Deficiency, Prostate Carcinoma Metastatic in the Bone, PSA Level Greater Than or Equal to Two, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
Carboplatin, Docetaxel, Laboratory Biomarker Analysis, Rucaparib Camsylate, Rucaparib
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 16, 2026, 7:56 PM EDT
Terminated Phase 2 Interventional Results available

Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC

NCT01995058
View directory record Official record
Conditions
Prostate Cancer, Castration Resistant Prostate Cancer, Prostatic Neoplasms
Interventions
cabozantinib, abiraterone, prednisone
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older · Male only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
20
States / cities
Scottsdale, Arizona • Sedona, Arizona • Tucson, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Sep 16, 2026, 7:56 PM EDT
Completed Phase 2 Interventional Results available

I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).

NCT03939689
View directory record Official record
Conditions
Metastatic Prostate Cancer, Castration-resistant Prostate Cancer, Prostatic Neoplasm, Cancer of the Prostate, Progressive mCRPC
Interventions
I-131-1095, Enzalutamide
Drug
Lead sponsor
Progenics Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
20
States / cities
Duarte, California • Los Angeles, California • Newport Beach, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 16, 2026, 7:56 PM EDT
Completed Phase 2 Interventional Results available

Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC

NCT02463799
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radium-223, Sipuleucel-T
Drug · Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
5
States / cities
Los Angeles, California • Washington D.C., District of Columbia • New Orleans, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2021 · Synced Sep 16, 2026, 7:56 PM EDT
Terminated Phase 2 Interventional Results available

Cabozantinib in Men With Castration-Resistant Prostate Cancer

NCT01703065
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Castration-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
Cabozantinib
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 3, 2018 · Synced Sep 16, 2026, 7:56 PM EDT
Completed Phase 2 Interventional Results available

A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)

NCT02384382
View directory record Official record
Conditions
Prostate Carcinoma Metastatic to the Bone, Castration Resistant Prostate Cancer
Interventions
Enzalutamide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
5
States / cities
Detroit, Michigan • Farmington Hills, Michigan • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated May 4, 2020 · Synced Sep 16, 2026, 7:56 PM EDT
Not yet recruiting Early Phase 1 Interventional

Chemical-Shift-Encoded MRI for Active Bone Marrow Dosimetry in Radiopharmaceutical Therapy

NCT07609225
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
3'-Deoxy-3'-[18F]-fluorothymidine, Chemical-shift-encoded MRI
Drug · Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 16, 2026, 7:56 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer

NCT02499835
View directory record Official record
Conditions
Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Soft Tissues, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Interventions
Pembrolizumab, pTVG-HP Plasmid DNA Vaccine
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Sep 16, 2026, 7:56 PM EDT
Active, not recruiting Phase 2 Interventional

Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer

NCT05502315
View directory record Official record
Conditions
Castration-resistant Prostate Cancer, Metastatic Cancer
Interventions
Cabozantinib, Nivolumab
Drug
Lead sponsor
Rana McKay, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
La Jolla, California • Chicago, Illinois • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 16, 2026, 7:56 PM EDT
Completed Not applicable Interventional Results available

Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer

NCT01812668
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
cabozantinib-s-malate, fluorine F 18 d-FMAU, positron emission tomography, pharmacological study, laboratory biomarker analysis
Drug · Radiation · Procedure + 1 more
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Sep 16, 2026, 7:56 PM EDT
Completed Phase 2 Interventional Results available

Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer

NCT03406858
View directory record Official record
Conditions
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
HER2Bi-Armed Activated T Cells, Laboratory Biomarker Analysis, Pembrolizumab
Biological · Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
19 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 2, 2023 · Synced Sep 16, 2026, 7:56 PM EDT
Withdrawn Phase 1 Interventional

A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer

NCT02396368
View directory record Official record
Conditions
Prostate Cancer, Bone-only Metastatic Castration-Resistant Prostate Cancer (CRPC)
Interventions
Tasquinimod, Radium 223
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2015 · Synced Sep 16, 2026, 7:56 PM EDT
Completed Phase 2 Interventional Results available

Determine Effect of Enzalutamide (MDV3100) on the Androgen Signaling Pathway in Correlation With the Anti-tumor Effects of Enzalutamide

NCT01091103
View directory record Official record
Conditions
Metastatic Progressive Castration-resistant Prostate Cancer
Interventions
Enzalutamide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Sep 16, 2026, 7:56 PM EDT
Completed Phase 2 Interventional Results available

Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone

NCT02023697
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
12
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Fort Myers, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced Sep 16, 2026, 7:56 PM EDT
Completed Phase 3 Interventional Results available

Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer

NCT00838201
View directory record Official record
Conditions
Cancer, Carcinoma, Castrate-Resistant Prostate Cancer, Prostate Cancer, Tumors
Interventions
Denosumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Male only
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
27
States / cities
Huntsville, Alabama • Anaheim, California • Laguna Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Sep 16, 2026, 7:56 PM EDT
Terminated Phase 2 Interventional Results available

ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer

NCT04159896
View directory record Official record
Conditions
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, Stage IVB Prostate Cancer AJCC v8
Interventions
Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981, Nivolumab
Drug · Biological
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Ann Arbor, Michigan • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 15, 2024 · Synced Sep 16, 2026, 7:56 PM EDT
Completed Phase 1 Interventional

Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)

NCT03076203
View directory record Official record
Conditions
Prostate Carcinoma Metastatic to the Bone, Stage IV Prostate Adenocarcinoma, Hormone-refractory Prostate Cancer
Interventions
Niraparib, Radium Ra 223 Dichloride
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
6
States / cities
Birmingham, Alabama • Chicago, Illinois • New Orleans, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 16, 2026, 7:56 PM EDT